x
Filter:
Filters applied
- EMAS Position Statements and Clinical Guides
- Stute, PetraRemove Stute, Petra filter
- Menopausal hormone therapyRemove Menopausal hormone therapy filter
- 2017 - 2022Remove 2017 - 2022 filter
Author
- Cano, Antonio2
- Chedraui, Peter2
- Goulis, Dimitrios G2
- Lambrinoudaki, Irene2
- Lopes, Patrice2
- Rees, Margaret2
- Anagnostis, Panagiotis1
- Bitzer, Johannes1
- Ceausu, Iuliana1
- Durmusoglu, Fatih1
- Erkkola, Risto1
- Jaremek, Jesse D1
- Karageorgiou, Vasilios1
- Kiesel, Ludwig1
- Lindén Hirschberg, Angelica1
- Meczekalski, Blazej1
- Mishra, Gita1
- Mueck, Alfred1
- Paschou, Stavroula A1
- Pines, Amos1
- Rogowicz-Frontczak, Anita1
- Senturk, Levent M1
- Simoncini, Tommaso1
- Slopien, Radoslaw1
EMAS Position Statements and Clincial Guides
2 Results
- Research Article
Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement
MaturitasVol. 131p91–101Published online: November 5, 2019- Petra Stute
- Areti Spyropoulou
- Vasilios Karageorgiou
- Antonio Cano
- Johannes Bitzer
- Iuliana Ceausu
- and others
Cited in Scopus: 21The European Menopause and Andropause Society (EMAS) aims to provide holistic consensus advice on the clinical management of menopausal women through its position statements and clinical guides [1]. EMAS’s healthcare model for healthy menopause covers physical, psychological and social functioning, and incorporates disability and disease [2]. This position statement sets out a model of care for the management of depressive symptoms and depressive episodes in peri- and postmenopausal women, integrating services provided by healthcare and allied professionals. - Research Article
Menopause and diabetes: EMAS clinical guide
MaturitasVol. 117p6–10Published online: August 22, 2018- Radoslaw Slopien
- Ewa Wender-Ozegowska
- Anita Rogowicz-Frontczak
- Blazej Meczekalski
- Dorota Zozulinska-Ziolkiewicz
- Jesse D. Jaremek
- and others
Cited in Scopus: 65Diabetes mellitus (DM) is a public health problem, especially in developed countries. It affects about 9.1% of the adult population in Europe and 13.3% in the United States of America [1]. The greater prevalence of DM in developed countries is broadly associated with ageing of the population [2]. Between 2015 and 2030, the world population aged over 60 years is projected to increase by 56%, from 901 million to 1.4 billion; by 2050 it is expected to reach nearly 2.1 billion [3]. These data suggest that the number of postmenopausal women with DM will grow substantially.